Healthcare Industry News: Lantheus Medical Imaging
News Release - April 1, 2015
AMAG Pharmaceuticals Announces New Management AppointmentsCompany Adds New External Affairs Function
WALTHAM, Mass., April 1, 2015 -- (Healthcare Sales & Marketing Network) -- AMAG Pharmaceuticals, Inc. (AMAG) today announced new management appointments which expand the company's ability to engage with external partners and stakeholders. Linda Lennox has joined the company as vice president of investor relations & corporate communications, assuming responsibilities from Kathryn Carr Payne who has been promoted to vice president of external affairs. In this newly established role for AMAG, Ms. Payne will direct the company's public affairs activities, which includes leading AMAG's public relations, policy and advocacy initiatives at the state and national level.
"Following the Lumara Health transaction, we made the strategic decision to create a new executive function within AMAG responsible for managing the company's external relations, including our engagement with policymakers, non-profit advocacy organizations and patients, to advance areas of mutual interest, such as expanding patient access to therapies," said William Heiden, president and chief executive officer. "I am confident that Katie's and Linda's complementary skill sets will help advance our business and policy objectives, while ensuring alignment with our overall corporate vision, values and patient-centric focus."
Ms. Payne joined AMAG in May 2014 from APCO Worldwide, a global public affairs and strategic communications firm based in Washington, D.C., where she led communications, policymaker outreach and brand-building programs designed to position healthcare companies, their products, issues and leadership to external audiences, including media, investors, customers and patients. Ms. Payne holds a bachelor's degree in writing and business management and a master's degree in communications from The Johns Hopkins University.
Ms. Lennox has 25 years of leadership experience with companies in the healthcare and energy sectors. Prior to joining AMAG, Ms. Lennox served as senior director, investor relations & corporate communications at Lantheus Medical Imaging, Inc., a privately held global diagnostic imaging company. Prior to that, Ms. Lennox served as vice president, investor & media relations at Critical Therapeutics, a publicly traded biotechnology/specialty pharmaceutical company. Prior to joining Critical Therapeutics, Ms. Lennox spent 15 years in positions of increasing responsibility at two separate publicly traded energy companies. Ms. Lennox started her career at Putnam Investments and Smith Barney, where she obtained her series 6, 7 and 63 licenses. She received a bachelor's degree in economics from the University of Vermont.
Inducement Equity Awards
In connection with Ms. Lennox's entering into employment with AMAG, Ms. Lennox will be granted (i) an option to purchase 9,500 shares of common stock and (ii) 2,500 restricted stock units. The option will have an exercise price equal to the closing price of AMAG's common stock on the grant date and will be exercisable in four equal annual installments beginning on the first anniversary of the grant date. The option will have a ten-year term and be subject to the terms and conditions of the stock option agreement pursuant to which the option will be granted. The restricted stock units will vest in three equal annual installments beginning on the first anniversary of the grant date and will be subject to the restricted stock unit agreement pursuant to which the restricted stock units will be granted. These equity awards will be granted without stockholder approval as inducements material to Ms. Lennox entering into employment with AMAG in accordance with NASDAQ Listing Rule 5635(c)(4).
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company with a focus on maternal health, anemia and cancer supportive care. The primary goal of AMAG is to bring to market therapies that provide clear benefits and improve patients' lives. In addition to continuing to pursue opportunities to make new advancements in patients' health and to enhance treatment accessibility, AMAG intends to continue to expand and diversify its portfolio through the in-license or purchase of additional pharmaceutical products or companies.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to statements regarding: Ms. Lennox's contributions and responsibilities are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.
Such risks and uncertainties include, among others, our ability to attract and retain key employees, and the resulting disruptions to our operations if we fail to do so and such other risks identified in our Securities and Exchange Commission (SEC) filings, including our Annual Report on Form 10-K for the year ended December 31, 2014 and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.
We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
AMAG Pharmaceuticals(R) is a registered trademark of AMAG Pharmaceuticals, Inc. Lumara Health(TM) is a trademark of Lumara Health Inc.
Source: AMAG Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.